So far, multiple phase I clinical trials focusing on CD47 suppression have been initiated and have shown limited results, largely due to toxicity concerns due to CD47’s ubiquitous expression in many non-tumour organ systems [162,163,164,165]. This evidence concerns the gene CD47 and neoplasm.